Er:YAG laser therapy in combination with GLUMA desensitizer reduces dentin hypersensitivity in children with molar-incisor hypomineralization: a randomized clinical trial

Zhao, Shuya; Zhou, Lisha; Jiang, Yuan; Xing, Xianghui

doi:10.1007/s10103-023-03944-6

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined therapies for MIH-related DH in children appear to be promising. A recent study [ 53 ] investigated the effectiveness of erbium-doped yttrium garnet (Er:YAG) laser and GLUMA desensitizer for DH in teeth affected by MIH in pediatric patients. Zhao et al concluded that the combination therapy of Er:YAG laser and GLUMA desensitizer had greater desensitizing effects than the use of the individual therapies and also positively impacted the oral health-related quality of life.…”

Section: Discussionmentioning

confidence: 99%

Molar Incisor Hypomineralization: Optimizing Treatment Protocols for Hypersensitivity: A Randomized Clinical Trial

Bardellini,

Amadori,

Rosselli

et al. 2024

Dentistry Journal

View full text Add to dashboard Cite

Dentin hypersensitivity (DH) is a common challenge in pediatric patients with molar incisor hypomineralization (MIH), stemming from enamel porosity or exposed dentin after enamel breakdown. This three-arm randomized controlled clinical trial aims to evaluate the effectiveness of three different desensitizing treatment protocols. The study was conducted on 39 children, aged 6–14 years old, with MIH and DH. Group A received casein phosphopeptide plus amorphous calcium phosphate fluoride (CPP-ACPF) mousse and sham light therapy, Group B received placebo mousse and photo-bio-modulation therapy (PMBT), and Group C received both CPP-ACPF mousse and PMBT. DH evaluation using a visual analogue scale was performed at multiple time points. Both CPP-ACPF mousse and PMBT individually demonstrated desensitizing effects on dental elements affected by MIH. While PMBT had a greater immediate effect, the combination of the two therapies proved most effective in reducing DH. The VAS scores were statistically lower in group C compared to groups A and B, both after the first session (p = 0.0001) and after 28 days (p = 0.0005). This study suggests promising avenues for managing DH in MIH patients, highlighting the potential of combined therapies, specifically CPP-ACPF mousse and PMBT, for enhanced clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%